MOUNT SINAI LIVER CANCER PROGRAM. 20th ANNIVERSARY. “LIVER CANCER: NOVEL CLINICAL AND TRANSLATIONAL ADVANCES”

Friday, October 3, 2025, 8:30 AM - 4:30 PM, Davis Auditorium and Zoom Hybrid, New York,


There has been a revolution in the landscape of therapies for liver cancer, both in hepatocellular carcinoma (HCC) and in cholangiocarcinoma (CCA). Targeted physicians are not totally aware of the impact of new therapies in HCC and CCA in the clinical practice. There is a need to educated clinicians on the landcape of therapies available and the sequencing to be used. In addition, they should be exposed on the advanced reported in the up-dated AASLD guidelines on the management of HCC reported in 2023. Finally, they should be educated on the cutting-edge research in liver cancer, particularly regarding new insights in the pathogenesis of the disease and new molecular and immune therapies. The program aims to both increase the knowledge and competence of the attendees along with improving the scientific insight on the understanding of the molecular basis of these lethal diseases based on recent discoveries. The meeting is intended to provide a summary of advances in science and clinical management of liver cancer, including the research conducted in Mount Sinai.

1. Define the molecular pathogenesis and targets for therapies in HCC and CCA
2. Discuss the current role of neoadjuvant and adjuvant therapies in the management of liver cancer.
3. Update the current AASLD proposed standard of management of advanced HCC with new immune combination therapies.
4. Describe cutting-edge research in liver cancer, particularly regarding new insights in the pathogenesis of the disease and new molecular and immune therapies, conducted at the Mount Sinai Liver Cancer Program-2024-25

$25 – MSHS Physicians and Allied Health Professionals

$50 – Physicians and Allied Health Professionals

$100 – Industry participants

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (7.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all accredited CE educational activities. All individuals in control of content of an activity accredited by ISMMS are expected to disclose all their financial relationships with ineligible companies existing within the prior 24 months. All relevant financial relationships have been mitigated and disclosed to learners before the activity takes place. 

Friday, October 3, 2025